BioPharmSignal logoBioPharmSignal

Biotech News

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock (SRRK)Scholar RockFDA / regulatory

ISEMBYLD is approved for use in all adults and children ≥2 years of age with SMA who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment ISEMBYLD recommended dose of 10 mg/kg showed a robust, clinically meaningful 2.2-point improvement in motor function as measured by the

Related news

SRRKScholar Rock2026-03-31 11:00 EST

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

SRRKScholar Rock2026-08-07 20:20 EST

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

View all latest news

Scholar Rock

Myostatin Biology Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways. Apitegromab Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal...

Recent company news

SRRKScholar Rock2026-09-11 22:25 EST

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

SRRKScholar Rock2026-09-02 12:00 EST

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

SRRKScholar Rock2026-08-27 12:00 EST

Scholar Rock to Present at Upcoming Investor Conferences

SRRKScholar Rock2026-08-21 13:06 EST

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

SRRKScholar Rock2026-08-14 20:15 EST

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
49.02 USD
Market cap
5.35B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States